Olema Pharmaceuticals, Inc. OLMA
We take great care to ensure that the data presented and summarized in this overview for Olema Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding OLMA
View all-
Bvf Inc San Francisco, CA9.14MShares$58.8 Million3.47% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.5MShares$35.4 Million2.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$25.8 Million1.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$25.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$23.7 Million0.12% of portfolio
-
Logos Global Management LP San Francisco, CA3.21MShares$20.7 Million5.07% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.68MShares$17.3 Million4.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.53MShares$16.3 Million0.0% of portfolio
-
State Street Corp Boston, MA1.97MShares$12.7 Million0.0% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V81.67MShares$10.7 Million0.02% of portfolio
Latest Institutional Activity in OLMA
Top Purchases
Top Sells
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at OLMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 17
2024
|
G. Walmsley Graham Director |
SELL
Open market or private purchase
|
Indirect |
700,761
-33.22%
|
$4,204,566
$6.75 P/Share
|
|
Dec 17
2024
|
G. Walmsley Graham Director |
SELL
Open market or private sale
|
Indirect |
700,761
-100.0%
|
$4,204,566
$6.75 P/Share
|
|
Dec 16
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+9.76%
|
$56,000
$4.87 P/Share
|
|
Dec 11
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
14,522
-5.6%
|
$130,698
$9.03 P/Share
|
|
Dec 11
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
13,614
-1.11%
|
$122,526
$9.03 P/Share
|
|
Dec 11
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
8,137
-0.53%
|
$73,233
$9.03 P/Share
|
|
Dec 11
2024
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
57,174
-9.61%
|
$514,566
$9.03 P/Share
|
|
Dec 11
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
18,356
-1.63%
|
$165,204
$9.03 P/Share
|
|
Dec 10
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,283
-9.27%
|
$119,547
$9.37 P/Share
|
|
Dec 10
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
SELL
Open market or private sale
|
Direct |
12,452
-1.99%
|
$112,068
$9.38 P/Share
|
|
Dec 10
2024
|
Cyrus Harmon |
SELL
Open market or private sale
|
Direct |
8,256
-1.06%
|
$74,304
$9.37 P/Share
|
|
Dec 10
2024
|
Sean Bohen PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
52,328
-14.9%
|
$470,952
$9.37 P/Share
|
|
Dec 10
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
SELL
Open market or private sale
|
Direct |
16,803
-2.9%
|
$151,227
$9.37 P/Share
|
|
Dec 09
2024
|
Naseem Zojwalla CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+26.62%
|
-
|
|
Dec 09
2024
|
David C. Myles CH. DISCOV. & NON-CLIN DEV OFF |
BUY
Grant, award, or other acquisition
|
Direct |
48,750
+7.24%
|
-
|
|
Dec 09
2024
|
Cyrus Harmon |
BUY
Grant, award, or other acquisition
|
Direct |
29,250
+3.61%
|
-
|
|
Dec 09
2024
|
Sean Bohen PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
204,750
+36.83%
|
-
|
|
Dec 09
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Grant, award, or other acquisition
|
Direct |
68,250
+10.55%
|
-
|
|
Dec 04
2024
|
Bvf Partners L P Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,369,704
-35.73%
|
-
|
|
Nov 15
2024
|
Shane William Charles Kovacs CH. OPERATING & FINANCIAL OFF. |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.67%
|
$175,000
$7.02 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 403K shares |
|---|---|
| Exercise of conversion of derivative security | 132K shares |
| Other acquisition or disposition | 386K shares |
| Sale (or disposition) back to the issuer | 3.37M shares |
|---|---|
| Open market or private sale | 4.67M shares |
| Open market or private purchase | 701K shares |
| Other acquisition or disposition | 481K shares |